4 Results for "

T-cell priming

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "T-cell priming" in MCE Product Catalog:

Cat. No.: HY-159649
CAS No.: 2618418-12-3
Research Areas:  

Inflammation/Immunology Cancer

BMS-986408 is an orally active inhibitor of DGKα and DGKζ, with IC50 values of 0.0003 μM and 0.002 μM, respectively. BMS-986408 activates intratumoral T cell responses, enhances the priming and expansion of tumor-reactive T cells in tumor-draining lymph nodes, and functions as an immunostimulant. BMS-986408 can be used in the research of tumors .
loading...
    loading...
Cat. No.: HY-P991525
CAS No.: 2923542-55-4

Target:  

Fc Receptor (FcR)

Research Areas:  

Cancer

2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8 + T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma .
loading...
    loading...
Cat. No.: HY-130116A
CAS No.: 2243079-27-6
Target:  

STING

Research Areas:  

Cancer

IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
loading...
    loading...
Cat. No.: HY-P991801

Target:  

IFNAR PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse IFN Beta Antibody (MIB-5E9.1) is an antibody targeting mouse IFN-β. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) blocks the IFN-β signaling pathway, abolishes LPS-induced upregulation of B7H1 and GITRL in dendritic cells, restores dendritic cell-dependent T cell proliferation impaired by LPS exposure, and reverses LPS-induced upregulation of PD-1 on splenic T cells. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) reduces LPS-induced upregulation of GITR on splenic T cells and inhibits LPS-mediated Treg priming .
loading...
    loading...